Mediterr J Rheumatol 2017;28(4):210-1
A new player in psoriatic arthritis: a JAK inhibitor
Authors Information

Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

  1. Sakkas L I, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 2013;43:325-34.
  2. Matthew A J, Bird P, Gupta A, George R E, Danda D. Magnetic resonance imaging (MRI) of the feet demonstrates subclinical inflammatory disease in cutaneous psoriasis patients without clinical arthritis. Ann Rheum Dis 2017;76:727.
  3. Sakkas L I, Bogdanos D P. Are psoriasis and psoriatic arthritis the same disease? The Il-23/IL-17 axis data. Autoimmune Rev 2017;16:10-5.
  4. Gossec L, Smolen J S, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
  5. Coates L C, Kavanaugh A, Mease P J, Soriano E R, Laura Acosta-Felquer M, Armstrong A W, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016;68:1060-71.
  6. Mease P, Hall S, FitzGerald O, van der Heijde D, Merola J F, Avila-Zapata F, et al. Tofacinib versus adalimumab in psoriatic arthritis. New Engl J Med 2017;377:1537-50.
  7. Gladman D, Rigby W, Azevedo V F, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with inadequate response to TNF inhibitors. New Engl J Med 2017;377:1525-36.
  8. Ghoreschi K, Laurence A, O’Shea J J. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-87.
  9. Richlin C, Rahman P, Kavanaugh A, McInnes I B, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapry:6-month, and 1-year results of the phase 3, multicenter, double-blind, placebo-controlled, randomized PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9.
  10. Kavanaugh A, McInnes I B, Mease P J, Hall S, Chinoy H, Kivitz A J, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: Results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 2016;43:1713-7.